Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310500612> ?p ?o ?g. }
- W4310500612 endingPage "253" @default.
- W4310500612 startingPage "240" @default.
- W4310500612 abstract "IntroductionDirect-acting antivirals (DAAs) have improved treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease (CKD). To facilitate the 2022 update of the Kidney Disease: Improving Global Outcomes (KDIGO) guideline for CKD patients with HCV, we systematically reviewed DAA regimens in patients with CKD stages G4 and G5 nondialysis (G4–G5ND), CKD stage G5 on dialysis (G5D), and kidney transplant recipients (KTRs).MethodsWe conducted a systematic review by searching PubMed, Embase, Cochrane, CINAHL, and ClinicalTrials.gov through February 1, 2022, and conferences from 2019 to 2021. Studies of HCV-infected patients with CKD G4–G5ND, G5D, and KTRs treated with specified DAA regimens were included. Outcomes included death at 6 months or later, sustained virologic response at 12 weeks (SVR12), serious adverse events (SAEs) attributed to DAA, and treatment discontinuation because of adverse events. Maximum likelihood meta-analyses were determined; certainty of evidence was assessed per GRADE (Grading of Recommendations Assessment, Development, and Evaluation).ResultsWe identified 106 eligible studies (22 reported on CKD G4–G5ND, 69 on CKD G5D, and 29 on KTRs). In each population, the majority of DAA regimens achieved SVR12 ≥ 93%. We found generally low quality of evidence of low risk of SAEs (mostly 0%, up to 2.9%) and low risk of discontinuation because of adverse events (mostly 0%−5%). Across 3 unadjusted observational studies in KTRs, the risk of death after DAA treatment was substantially lower than without treatment (summary odds ratio, 0.16; 95% CI, 0.04–0.61).ConclusionCombination DAA regimens are safe and highly effective in patients with advanced CKD, on dialysis, and with kidney transplants." @default.
- W4310500612 created "2022-12-11" @default.
- W4310500612 creator A5000950219 @default.
- W4310500612 creator A5011120853 @default.
- W4310500612 creator A5035092043 @default.
- W4310500612 creator A5056355381 @default.
- W4310500612 creator A5059680403 @default.
- W4310500612 date "2023-02-01" @default.
- W4310500612 modified "2023-10-01" @default.
- W4310500612 title "A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD" @default.
- W4310500612 cites W1874082200 @default.
- W4310500612 cites W1908153784 @default.
- W4310500612 cites W2061211489 @default.
- W4310500612 cites W2095994762 @default.
- W4310500612 cites W2098923148 @default.
- W4310500612 cites W2110280174 @default.
- W4310500612 cites W2165010366 @default.
- W4310500612 cites W2234102010 @default.
- W4310500612 cites W2272258032 @default.
- W4310500612 cites W2296452901 @default.
- W4310500612 cites W2337034071 @default.
- W4310500612 cites W2460697116 @default.
- W4310500612 cites W2465804291 @default.
- W4310500612 cites W2507376318 @default.
- W4310500612 cites W2531269403 @default.
- W4310500612 cites W2554701966 @default.
- W4310500612 cites W2567208426 @default.
- W4310500612 cites W2573099294 @default.
- W4310500612 cites W2578055747 @default.
- W4310500612 cites W2587472693 @default.
- W4310500612 cites W2588681363 @default.
- W4310500612 cites W2594758046 @default.
- W4310500612 cites W2600267429 @default.
- W4310500612 cites W2602725067 @default.
- W4310500612 cites W2608263244 @default.
- W4310500612 cites W2608685329 @default.
- W4310500612 cites W2612344040 @default.
- W4310500612 cites W2618332520 @default.
- W4310500612 cites W2618542764 @default.
- W4310500612 cites W2626751913 @default.
- W4310500612 cites W2734474168 @default.
- W4310500612 cites W2751504895 @default.
- W4310500612 cites W2761085897 @default.
- W4310500612 cites W2762304914 @default.
- W4310500612 cites W2765762303 @default.
- W4310500612 cites W2769430510 @default.
- W4310500612 cites W2777886565 @default.
- W4310500612 cites W2783368644 @default.
- W4310500612 cites W2793066001 @default.
- W4310500612 cites W2793357379 @default.
- W4310500612 cites W2795236262 @default.
- W4310500612 cites W2796523456 @default.
- W4310500612 cites W2799447244 @default.
- W4310500612 cites W2800358870 @default.
- W4310500612 cites W2800563576 @default.
- W4310500612 cites W2801832078 @default.
- W4310500612 cites W2802683858 @default.
- W4310500612 cites W2803034834 @default.
- W4310500612 cites W2804832579 @default.
- W4310500612 cites W2805807940 @default.
- W4310500612 cites W2808554001 @default.
- W4310500612 cites W2883424127 @default.
- W4310500612 cites W2885103621 @default.
- W4310500612 cites W2888196516 @default.
- W4310500612 cites W2889035601 @default.
- W4310500612 cites W2889542600 @default.
- W4310500612 cites W2891967139 @default.
- W4310500612 cites W2894887727 @default.
- W4310500612 cites W2896996128 @default.
- W4310500612 cites W2898378712 @default.
- W4310500612 cites W2898584884 @default.
- W4310500612 cites W2898645176 @default.
- W4310500612 cites W2900006662 @default.
- W4310500612 cites W2901843950 @default.
- W4310500612 cites W2906376528 @default.
- W4310500612 cites W2907181694 @default.
- W4310500612 cites W2907321304 @default.
- W4310500612 cites W2913706624 @default.
- W4310500612 cites W2913922515 @default.
- W4310500612 cites W2915264331 @default.
- W4310500612 cites W2921098283 @default.
- W4310500612 cites W2921919494 @default.
- W4310500612 cites W2922105624 @default.
- W4310500612 cites W2925087819 @default.
- W4310500612 cites W2934270914 @default.
- W4310500612 cites W2937346789 @default.
- W4310500612 cites W2944896029 @default.
- W4310500612 cites W2950823694 @default.
- W4310500612 cites W2952098072 @default.
- W4310500612 cites W2967243914 @default.
- W4310500612 cites W2973838632 @default.
- W4310500612 cites W2973954803 @default.
- W4310500612 cites W2981238845 @default.
- W4310500612 cites W2982216008 @default.
- W4310500612 cites W2985173551 @default.
- W4310500612 cites W2990257103 @default.
- W4310500612 cites W2995422882 @default.
- W4310500612 cites W2995515444 @default.